-
Your selected country is
Finland
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Anti-TCR-γ/δ PE
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.
Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.
Anti–TCR-γ/δ is intended for in vitro diagnostic use in the identification of cells expressing TCR-γ/δ antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.
Development References (13)
-
Borst J, van Dongen JJ, Bolhuis RL, et al. Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a monoclonal antibody.. J Exp Med. 1988; 167(5):1625-44. (Biology). View Reference
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. H42-A2. 2007. (Biology).
-
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
-
Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
-
Knowles DM. Knowles DM, Thompson DD, ed. Neoplastic Hematopathology. Philadelphia, PA: Williams & Wilkins; 2001.
-
Lanier L, Federspiel N, Ruitenberg J, et al. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8-T lymphocytes. J Exp Med. 1987; 165:1076-1094. (Biology).
-
Lanier LL, Ruitenberg J, Bolhuis RL, Borst J, Phillips JH, Testi R. Structural and serological heterogeneity of gamma/delta T cell antigen receptor expression in thymus and peripheral blood.. Eur J Immunol. 1988; 18(12):1985-92. (Biology). View Reference
-
Lanier LL, Serafini AT, Ruitenberg JJ, et al. The γ T-cell antigen receptor. J Clin Immunol. 1987; 7:429-440. (Biology).
-
NCCLS document. 2001. (Biology).
-
Spits H, Paliard X, Vandekerckhove Y, van Vlasselaer P, de Vries JE. Functional and phenotypic differences between CD4+ and CD4- T cell receptor-γ δ clones from peripheral blood. J Immunol. 1991; 147:1180-1188. (Biology).
-
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
-
Testi R, Lanier LL. Functional expression of CD28 on T cell antigen receptor γ/δ-bearing T lymphocytes. Eur J Immunol. 1989; 19:185-188. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostic Use.
23-22942-00
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.